catechin has been researched along with Leiomyosarcoma in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Dhima, IT; Evangelou, AM; Gkiouli, MI; Kalfakakou, V; Karkabounas, SC; Palatianou, ME; Peschos, D; Ragos, VN; Simos, YV | 1 |
| Kitamura, M; Kondo, A; Li, B; Takeda, T; Tsuiji, K; Wong, TF; Yaegashi, N | 1 |
2 other study(ies) available for catechin and Leiomyosarcoma
| Article | Year |
|---|---|
Modulation of cisplatin cytotoxic activity against leiomyosarcoma cells by epigallocatechin-3-gallate.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Catechin; Cell Cycle; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Cisplatin; Inhibitory Concentration 50; Leiomyosarcoma; Mitochondria; Rats, Wistar | 2018 |
Epigallocatechin-3-gallate potentiates curcumin's ability to suppress uterine leiomyosarcoma cell growth and induce apoptosis.
Topics: Apoptosis; Biological Availability; Catechin; Cell Line, Tumor; Cell Proliferation; Curcumin; Drug Synergism; Female; Humans; Leiomyosarcoma; Oncogene Protein v-akt; Receptors, Laminin; Ribosomal Protein S6 Kinases; Signal Transduction; TOR Serine-Threonine Kinases; Uterine Neoplasms | 2013 |